Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1055726 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.04Day +0.97%Mkt cap $86M1Y −27.3%Off 52W high −65.1%Vol (1Y) 78.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest17.7% of sh out |
| Days to cover9.2d |
| 13F net flow (QoQ)−3.15% |
| Top-10 13F concentration81.8% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$0 |
| Earnings (TTM)-$84.9M |
| ROE−183.5% |
| Net margin−130000.0% |
| Sales growth 3Y−81.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−40.2% |
| 1Y−27.3% |
| 3Y−83.7% |
| 5Y−99.0% |
| 10Y−99.1% |
| Since incept. (ann.)−20.6% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)78.8% |
| Ann. volatility (3Y)87.1% |
| Sharpe (1Y)−0.03 |
| Sharpe (3Y)−0.24 |
| Max drawdown (1Y)−66.4% |
| Max drawdown (3Y)−93.0% |
| Beta (3Y vs SPY)1.51 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 9.3M | $16M | 13.52% | −5.1% |
| JANUS HENDERSON GROUP PLC | 3.3M | $6M | 4.79% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.9M | $5M | 4.20% | new |
| Boxer Capital Management, LLC | 2.4M | $4M | 3.43% | −2.1% |
| D. E. Shaw & Co., Inc. | 2.2M | $4M | 3.20% | −0.9% |
| ADAR1 Capital Management, LLC | 1.5M | $3M | 2.13% | −1.0% |
| MILLENNIUM MANAGEMENT LLC | 1.4M | $2M | 2.04% | +0.5% |
| Eversept Partners, LP | 1.0M | $2M | 1.50% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.28 | — | $0 | −100.0% |
| 2025-12-31 | 2026-03-12 | — | — | $0 | −100.0% |
| 2025-09-30 | 2025-11-10 | −$0.87 | — | $0 | — |
| 2025-06-30 | 2025-08-12 | −$0.61 | — | $0 | −100.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable Segments 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
